Allogeneic NK cell Therapy(Escure Biotechnology)
N/A
Report date: 2024/04/12 20:03:58
Base Information
Drug NameAllogeneic NK cell Therapy(Escure Biotechnology)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[7]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEscure Biotechnology CorpBeijing Kejian Biotechnology Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesBeijing Kejing Biotechnology Co Ltd
Active IndicationsN/A
Inactive Indications +[7]
Other Information
ATC CodeN/A
Related LinksN/A